Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors

Cancer Research

Volumn 66, Issue 3, 2006, Pages 1270-1276

  Thomas, Maria A ^a   Spencer, Jacqueline F ^a   La Regina, Marie C ^b   Dhar, Debanjan ^a   Tollefson, Ann E ^a   Toth, Karoly ^a   Wold, William S M ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ONCOLYTIC VIRUS;

ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER MODEL; CANCER THERAPY; CELL LINE; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOFLUORESCENCE; NONHUMAN; PRIORITY JOURNAL; SYRIAN HAMSTER; VIRUS REPLICATION; WESTERN BLOTTING; XENOGRAFT;

ADENOVIRUSES, HUMAN; ANIMALS; CELL LINE, TUMOR; CRICETINAE; DISEASE MODELS, ANIMAL; GENETIC VECTORS; HUMANS; IMMUNOCOMPETENCE; LUNG; MESOCRICETUS; TISSUE DISTRIBUTION; VIRUS REPLICATION;

EID: 32944474223     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3497     Document Type: Article

References (20)

1. Ginsberg HS, Moldawer LL, Sehgal PB, et al. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci USA 1991;88:1651-5.
2. Hjorth RN, Bonde GM, Pierzchala WA, et al. A new hamster model for adenoviral vaccination. Arch Virol 1988;100:279-83.
3. Duncan SJ, Gordon FC, Gregory DW, et al. Infection of mouse liver by human adenovirus type 5. J Gen Virol 1978;40:45-61.
4. Liu TC, Hallden G, Wang Y, et al. An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency. Mol Ther 2004;9:786-803.
5. Thomas MA, Spencer JF, Wold WSM. The use of the Syrian hamster as an animal model for oncolytic adenovirus vectors. In: Tollefson AE, Wold WSM, editors. Adenovirus Methods and Protocols. 2nd ed. Humana Press. In press.
6. Doronin K, Toth K, Kuppuswamy M, Krajcsi P, Tollefson AE, Wold WSM. Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus. Virology 2003;305:378-87.
7. Lichtenstein DL, Toth K, Doronin K; Tollefson AE, Wold WSM. Functions and mechanisms of action of the adenovirus E3 proteins. Int Rev Immunol 2004;23:75-111.
8. Tollefson AE, Scaria A, Hermiston TW, Ryerse JS, Wold LJ, Wold WSM. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J Virol 1996;70:2296-306.
9. Toth K, Djeha H, Ying BL, et al. An oncolytic adenovirus vector combining enhanced cell-to-cell spreading, mediated by the ADP cytolytic protein, with selective replication in cancer cells with deregulated Wnt signaling. Cancer Res 2004;64:3638-44.
10. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996;70:7498-509.
11. Tarakanova VL, Wold WS. Transforming growth factor b1 receptor II is downregulated by E1A in adenovirus-infected cells. J Virol 2003;77:9324-36.
12. Toth K, Spencer JF, Tollefson AE, et al. Cotton rat tumor model for the evaluation of oncolytic adenoviruses. Hum Gene Ther 2005;16:139-46.
13. Reid TR, Freeman S, Post L, McCormick F, Sze DY. Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther 2005;12:673-81.
14. Bernt KM, Ni S, Tieu AT, Lieber A. Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy. Cancer Res 2005;65:4343-52.
15. Hallden G, Hill R, Wang YH, et al. Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy. Mol Ther 2003;8:412-24.
16. Ternovoi W, Le LP, Belousova N, Smith BF, Siegal GP, Curiel DT. Productive replication of human adenovirus type 5 in canine cells. J Virol 2005;79:1308-11.
17. Wang YH, Hallden G, Hill R, et al. E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat Biotechnol 2003;21:1328-35.
18. Ganly I, Mautner V, Balmain A. Productive replication of human adenoviruses in mouse epidermal cells. J Virol 2000;74:2895-9.
19. Pacini DL, Dubovi EJ, Clyde WA, Jr. A new animal model for human respiratory tract disease due to adenovirus. J Infect Dis 1984;150:92-7.
20. Kataoka M, Schumacher G, Cristiano RJ, Neely Atkinson E, Roth J, Mukhopadhyay T. An agent that increases tumor suppressor transgene product coupled with systemic transgene delivery inhibits growth of metastatic lung cancer in vivo. Can Res 1998;58:4761-5.